Grants closing in September 2026

Funds fundamental (Basic) and Credentialing cancer research addressing biological mechanisms of cancer onset, growth, and spread, as well as psychosocial mechanisms. Proposal types include Research Project, Consortium, and Unique High-Risk. Young Investigator Grants must be submitted under a separate YIG call.

Dedicated to basic research uncovering mechanisms driving cancer onset, growth, and spread. Intended for proposals within the Basic research and Credentialing phases. Aims to address knowledge gaps and identify new leads for prevention, diagnosis, and treatment.

For senior researchers at the consolidation/leadership stage who obtained their PhD within 15 years of 1 March 2026. Applicants must demonstrate academic qualities exceeding international peer group norms and established leadership/mentorship skills. Proposals must be written in English.

Open to PhD holders of any nationality with up to 8 years of post-PhD research experience. European Fellowships require hosting in an EU Member State or Horizon Europe associated country; Global Fellowships require EU nationals or long-term residents conducting research in a third country with a mandatory 12-month return phase. Applicants cannot have resided in the host country for more than 12 months in the last 3 years (mobility rule applies).

Open to postdoctoral researchers of any nationality with max 8 years post-PhD experience. European Fellowships require a host in an EU/associated country; Global Fellowships require EU/associated country nationals or long-term residents working in a third country then returning to Europe. Researchers must not have resided in the host country for more than 12 months in the last 3 years (standard MSCA mobility rule). Open to all scientific fields including Euratom research.

Individual postdoctoral fellowships for researchers up to 8 years post-PhD. European Fellowships are open to any nationality hosted in an EU Member State or Horizon Europe Associated Country; Global Fellowships require EU nationals or long-term residents for an outgoing phase in a non-associated third country plus a mandatory 12-month return phase. Full-time commitment required; MSCA mobility rules apply.

Horizon Europe RIA under the EU Cancer Mission supporting development of validated microbiome tools for early cancer prediction before disease onset, including AI risk modelling, longitudinal cohort studies, and comparison with liquid biopsy tests. Proposals must address multiple cancer types where possible and collaborate with large cohorts/registries. Lump sum grant; one grant expected.

Supports exploratory applied research on testable and existing AI applications (use cases) focused on labour-saving AI. Conducted through new practice-oriented research activities at universities of applied sciences.

Funds development of advanced multiscale Virtual Human Twin (VHT) models for cancer research, focusing on cancers with limited treatment options, rare/paediatric cancers, and refractory cancers. Proposals must integrate AI tools for multimodal FAIR data analysis, validate VHTs with longitudinal patient data, and make assets available via UNCAN.eu and the Advanced VHT Platform. Interdisciplinary consortia including clinicians, patient representatives, AI experts, and SMEs are expected.

Research and Innovation Action under the EU Cancer Mission (HORIZON-MISS-2026-02), with a total budget of €22.186M and 3 indicative grants of €7M–€8M each. Full scope details are in the specific work programme topic description.

Research and Innovation Action under the EU Cancer Mission (HORIZON-MISS-2026-02), with a total budget of €15M and 3 indicative grants of around €5M each. Full scope details are in the specific work programme topic description.

Innovation Action under the EU Cancer Mission (HORIZON-MISS-2026-02), with a total budget of €7M and 1 indicative grant of around €7M. Full scope details are in the specific work programme topic description.

Coordination and Support Action under the EU Cancer Mission (HORIZON-MISS-2026-02), with a total budget of €5M and 1 indicative grant of around €5M. Full scope details are in the specific work programme topic description.

Research and Innovation Action under the EU Cancer Mission (HORIZON-MISS-2026-02), with a total budget of €25M and 5 indicative grants of €5M–€6M each. Full scope details are in the specific work programme topic description.

Part of the EU Cancer Mission call HORIZON-MISS-2026-02, this Research and Innovation Action topic has a total budget of €15M with one indicative grant. Full topic description available via the parent call page.

Horizon Europe RIA under the Cancer Mission calling for development of advanced multiscale Virtual Human Twin (VHT) models integrating AI and multimodal patient data to understand cancer onset/progression and personalise treatments. Proposals must include multidisciplinary consortia (medical, AI, patient representatives, SMEs) and share data/models via UNCAN.eu and the Advanced VHT Platform under open science principles. Clinical studies may be included with a dedicated annex.

Supports translation of KWF-funded innovations toward real-world application. Eligible only for ongoing or recently completed KWF projects (up to 1 year after completion). Covers steps such as external expertise, regulatory preparation, or business case development.

Add-on funding for ongoing or recently completed KWF-funded projects (incl. KWF-PPP, TTW Technology for Oncology, KWF-NWO early detection) that have reached at least TRL 3. Supports translational pathway definition, targeted development/validation, and regulatory/implementation preparation. TTO commitment letter mandatory; collaboration with TTO of applicant's research institution required.

Open to established researchers or teams led by an established researcher based at eligible organisations in the UK, Republic of Ireland, or low- and middle-income countries (excluding India and mainland China). Research must fit within Wellcome's Discovery Research remit and have potential to improve human life, health, and wellbeing across any discipline including STEM, humanities, social science, and public health.

Open to established researchers or teams led by an established researcher based at eligible not-for-profit organisations in the UK, Republic of Ireland, or low- and middle-income countries (excluding India and mainland China). Research must fit within Wellcome's Discovery Research remit and have potential to improve human life, health, and wellbeing across any discipline including STEM, humanities, social science, and public health.

PPP subsidy for Dutch SMEs and research organisations participating in international R&D consortia focused on cell and gene therapies (CGT) and Organ-on-Chip (OoC) technologies (TRL 4–7). Healthcare providers and foundations are not eligible. International partners must secure their own funding. Co-funding (in-kind and/or cash) by all partners is required.

Open to scientists, clinicians or healthcare workers based in UK universities, medical schools, hospitals or research institutions. Supports ambitious, long-term programmes in basic or early-stage translational cancer research. Applicants must hold a post fully funded by a national Higher Education Funding Council, NHS or equivalent; collaborative teams and multidisciplinary approaches are encouraged. Closed scheme — contact required before applying.

For mid-career researchers at UK universities, medical schools, hospitals or research institutions seeking to develop independent research programmes in cancer biology. Applicants must hold a salaried independent position funded by a Higher Education Funding Council, NHS or equivalent. Clinical trials, drug discovery as sole function, and early detection/prevention are excluded. Closed scheme requiring prior contact with CRUK before applying.

Links questions from Defence units to practice-oriented research at universities of applied sciences. Supports exploratory practice-oriented research focused on Defence issues. Requires collaboration between Defence and applied research institutions.